99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer

Journal of Nuclear Medicine

Volumn 54, Issue 8, 2013, Pages 1369-1376

  Hillier, Shawn M ^a   Maresca, Kevin P ^a   Lu, Genliang ^a   Merkin, Ross D ^a   Marquis, John C ^a   Zimmerman, Craig N ^a   Eckelman, William C ^a   Joyal, John L ^a   Babich, John W ^a  

^a Clinical Research   (United States)

Author keywords

Imaging; Prostate cancer; PSMA; SPECT

Indexed keywords

2 (PHOSPHONOMETHYL)PENTANEDIOIC ACID; 2,2' [[2,2' [AZANEDIYLBIS(METHYLENE)]BIS(1H IMIDAZOLE 2,1 DIYL)]DIACETIC ACID] TC 99M; 2,2',2'',2''' [[2,2' [2,2' [AZANEDIYLBIS(METHYLENE)]BIS(1H IMIDAZOLE 2,1 DIYL)]BIS(ACETYL)]BIS(AZANETRIYL)]TETRAACETIC ACID TC 99M; CHELATING AGENT; GLUTAMIC ACID; GLUTARIC ACID DERIVATIVE; LYSINE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; UREA; ACETIC ACID DERIVATIVE; DIAGNOSTIC AGENT; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; PROTEINASE INHIBITOR; TECHNETIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; BLADDER; CANCER CELL CULTURE; COMPETITIVE INHIBITION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG PROTEIN BINDING; DRUG SPECIFICITY; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; KIDNEY; MOLECULAR IMAGING; MOUSE; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DETERMINATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TEMPERATURE SENSITIVITY; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; IMAGING; MALE; METABOLISM; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR; PSMA; RADIOCHEMISTRY; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

IMAGING; PROSTATE CANCER; PSMA; SPECT;

ACETATES; ANIMALS; ANTIGENS, SURFACE; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CHELATING AGENTS; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMIC ACID; HUMANS; LYSINE; MALE; MICE; MOLECULAR IMAGING; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; RADIOCHEMISTRY; TECHNETIUM; UREA;

EID: 84881417445     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.116624     Document Type: Article

References (41)

1. Kelloff GJ, Sullivan DC, Baker H, et al. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark. 2007;3: 1-33.
2. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary approach. Radiology. 2007;243:28-53.
3. Briganti A, Abdollah F, Nini A, et al. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. Eur Urol. 2012;61:1132-1138.
4. Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding prostate-specific membrane antigen. Cancer Res. 1993;53:227-230.
5. Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3: 81-85.
6. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987;7:927-935.
7. Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38:696-701.
8. Marchal C, Redondo M, Padilla M, et al. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. Histol Histopathol. 2004;19:715-718.
9. Pinto JT, Suffoletto BP, Bergin TM. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res. 1996;2: 1445-1451.
10. Smith-Jones PM, Vallabahajosula S, Goldsmith SJ, et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 2000;60:5237-5243.
11. Mesters JR, Henning K, Hilgenfeld R. Human glutamate carboxypeptidase II inhibition: structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA. Acta Crystallogr D Biol Crystallogr. 2007;63:508-513.
12. Barinka C, Byun Y, Dusich CL, et al. Interactions between human glutamate carboxypeptiase II and urea-based inhibitors:structural characterization. J Med Chem. 2008;51:7737-7743.
13. Maresca KP, Hillier SM, Femia FJ, et al. A series of halogenated heterodimeric inhibitors of prostate-specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem. 2009;52:347-357.
14. Hillier SM, Maresca KP, Femia FJ, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009;69: 6932-6940.
15. 123I- MIP1095 [abstract]. J Nucl Med. 2009;50(suppl):522P.
16. Alberto R, Schibli R, Waibel R, Abram U, Schubiger AP. Basic aqueous chemistry of [M(OH2)3(CO)3]1 (M5Re, Tc) directed towards radiopharmaceutical application. Coord Chem Rev. 1999;190-192:901-919.
17. Maresca KM, Wang J, Hillier SH, et al. Development of a simple kit for Tc-99m-MIP-1404, a single amino acid chelate (SAAC II) derived small molecule inhibitor of prostate specific membrane antigen (PSMA) for imaging prostate cancer [abstract]. J Nucl Med. 2012;53(suppl 1):159P.
18. Banerjee SR, Foss CA, Castanares M, et al. Synthesis and evaluation of technetium-99m-and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem. 2008;51:4504-4517.
19. 99mTc-radioimaging agents. Mol Pharm. 2009;6:790-800.
20. Maresca KP, Hillier SM, Lu G, et al. Small molecule inhibitors of PSMA incorporating technetium-99m for imaging prostate cancer: effects of chelate design on pharmacokinetics. Inorg Chim Acta. 2012;389:168-175.
21. Maresca KP, Marquis JC, Hillier SM, et al. Novel polar single amino acid chelates for technetium-99m tricarbonyl-based radiopharmaceuticals with enhanced renal clearance: application to octreotide. Bioconjug Chem. 2010;21:1032-1042.
22. 99mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors. Bioorg Med Chem Lett. In press.
23. Ascoli M. Internalization and degradation of receptor-bound choriogonadotropin in Leydig tumor cells. J Biol Chem. 1982;257:13306-13311.
24. Public Health Service Policy on Humane Care and Use of Laboratory Animals. National Institutes of Health Web site. http://grants.nih.gov/grants/ OLAW%20/ references/phspol.htm. Published 2002. Accessed May 15, 2013.
25. Tiffany CW, Lapidus RG, Merion A, Calvin DC, Slusher BS. Characterization of the enzymatic activity of PSM: comparison with brain NAALADase. Prostate. 1999;39:28-35.
26. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-1328.
27. Andriole GL, Grubb RL III, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310-1319.
28. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. U.S. Preventive Services Task Force Web site. http://www. uspreventiveservicestaskforce.org/prostatecancerscreening/ prostateart.htm. Published October 2011. Accessed May 13, 2013.
29. Delbeke D. Oncological applications of FDG PET imaging. J Nucl Med. 1999;40:1706-1715.
30. Hain SF, Maisey MN. Positron emission tomography in urological tumours. BJU Int. 2003;92:159-164.
31. Troyer JK, Beckett ML, Wright GL. Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate. 1997;30:232-242.
32. Troyer JK, Feng Q, Beckett ML, Wright GL. Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol Oncol. 1995;1:29-37.
33. Hövels AM, Heesakkers RA, Adang EM, et al. The diagnostic accuracy of CT and MR in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol. 2008;63:387-395.
34. 99mTc MDP scintigraphy. Radiology. 1993;186:845-849.
35. Bouchelouche K, Tagawa ST, Goldsmith SJ, Turkbey B, Capala J, Choyke P. PET/CT imaging and radioimmunotherapy of prostate cancer. Semin Nucl Med. 2011;41:29-44.
36. Guilarte TR, McGlothan JL, Foss CA, et al. Glutamate carboxypeptidase II levels in rodent brain using [125I]DCIT quantitative autoradiography. Neurosci Lett. 2005;387:141-144.
37. 18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res. 2008;14:3036-3043.
38. Foss CA, Mease RC, Fan H, et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res. 2005;11:4022-4028.
39. Chen Y, Foss CA, Byun Y, et al. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem. 2008;51:7933-7943.
40. Liu T, Wu LY, Kazak M, Berkman CE. Cell surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. Prostate. 2008; 68:955-964.
41. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23:4591-4601.